Lymphoma, Non-Hodgkin's

Please click on the protocol number for additional information.

CALGB 50303 : Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

ECOG E1F05: Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

ECOG E2402 : Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

ECOG E3402 : Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma

ECOG E3404: Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

ECOG S9704: Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

MAYO MC0485: A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone with Rituxan in Patients with Relapsed CD20+ B-Cell Non-Hodgkin's Lymphoma

MAYO H6Q-MC-JCBJ :  PRELUDE: Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin 

NCCTG N0682:  Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

SWOG S0016: Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaNon-Hodgkin's Lymphoma

Please contact the research office for more information.